Unknown

Dataset Information

0

A quantitative method for screening and identifying molecular targets for nanomedicine.


ABSTRACT: Identifying a molecular target is essential for tumor-targeted nanomedicine. Current cancer nanomedicines commonly suffer from poor tumor specificity, "off-target" toxicity, and limited clinical efficacy. Here, we report a method to screen and identify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis. In our proof-of-principle study, we used comparative flow cytometric screening to identify ICAM-1 as a potential target for metastatic melanoma (MM). We further evaluated ICAM-1 as a MM targeting moiety by characterizing its (1) tumor specificity, (2) expression level, (3) cellular internalization, (4) therapeutic function, and (5) potential clinical impact. Quantitation of ICAM-1 protein expression on cells and validation by immunohistochemistry on human tissue specimens justified the synthesis of antibody-functionalized drug delivery vehicles, which were benchmarked against appropriate controls. We engineered ICAM-1 antibody conjugated, doxorubicin encapsulating immunoliposomes (ICAM-Dox-LPs) to selectively recognize and deliver doxorubicin to MM cells and simultaneously neutralize ICAM-1 signaling via an antibody blockade, demonstrating significant and simultaneous inhibitory effects on MM cell proliferation and migration. This paper describes a novel, quantitative metric system that identifies and evaluates new cancer targets for tumor-targeting nanomedicine.

SUBMITTER: Guo P 

PROVIDER: S-EPMC5603366 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

A quantitative method for screening and identifying molecular targets for nanomedicine.

Guo Peng P   Yang Jiang J   Bielenberg Diane R DR   Dillon Deborah D   Zurakowski David D   Moses Marsha A MA   Auguste Debra T DT  

Journal of controlled release : official journal of the Controlled Release Society 20170322


Identifying a molecular target is essential for tumor-targeted nanomedicine. Current cancer nanomedicines commonly suffer from poor tumor specificity, "off-target" toxicity, and limited clinical efficacy. Here, we report a method to screen and identify new molecular targets for tumor-targeted nanomedicine based on a quantitative analysis. In our proof-of-principle study, we used comparative flow cytometric screening to identify ICAM-1 as a potential target for metastatic melanoma (MM). We furthe  ...[more]

Similar Datasets

| S-EPMC5553769 | biostudies-other
| S-EPMC5923273 | biostudies-literature
| S-EPMC5840842 | biostudies-literature
| S-EPMC6377634 | biostudies-literature
| S-EPMC3785445 | biostudies-literature
| S-EPMC6204767 | biostudies-literature
| S-EPMC3922837 | biostudies-literature
| S-EPMC10296532 | biostudies-literature
2023-12-01 | GSE247884 | GEO
| S-EPMC8608496 | biostudies-literature